Published :
Tables : 46
Figures : 42
Category : Healthcare
No. of Pages : 217
Report Code : HC-U9948
P2X7 Receptor Antagonists Market Overview: P2X7 receptor, an ATP-gated and non-selective cation channel that can regulate inflammatory disease has been implicated. The release of pro-inflammatory cytokines can be caused by the activation of the P2X7 channel by high levels of adenosine triphosphate (ATP). This has been linked to a wide range of diseases. There is currently no P2X7 antagonist on the market. Clinical trials have not yet begun to identify any P2X7 antagonists. P2X7R, a subtype of the seven purinergic P2X7 receptors that are ATP-gated, non-selective Cation Channels, is unique. There have been reports that P2X7R plays a pathological role in a variety of diseases, including arthritis, inflammatory bowel disease, neurodegenerative disorders, chronic pain, mood disorders, and cancers. Many pharmaceutical companies have attempted to develop a clinical candidate for P2X7R. P2X7 receptor, an ATP-gated and non-selective cation channel, is associated with a variety of inflammatory disorders. P2X7 receptor antagonists are therapeutic agents. Pain management is a common use of opioid medications. P2X7R, a subtype of the seven purinergic P2X receptors (ATP-gated nonselective Cation Channels), is unique. The pathological role of P2X7R in various diseases has been documented, including neurodegenerative diseases and chronic pain, mood disorders, cancers, and arthritis. A P2X7 Receptor Antagonist, or RA, is a pain medication that blocks the brain's activity of the ligand. The P2X7 Receptor is an important molecule that initiates inflammatory processes within the body. The approval and launch of an alternative pain management option are expected to be a breakthrough in this space. P2X7 has been linked to major depression. Animal studies have also shown that P2X7 antagonists can cause P2X7 to act in a way similar to antidepressants. Inflammation, mood disorders, and depression are all possible areas where P2X7 may be involved. Its antagonism could also help to modify treatment. Numerous research studies have shown that P2X7 channels are activated by the pro-inflammatory cytokines IL-1b, and IL-18. Extracellular ATP has a low affinity for P2X7, compared to other purinergic ion channel channels (P2X4, P2X3, etc.). The therapeutic benefits of P2X7 receptor antagonists are significant, since P2X7 receptors are associated with inflammation regulation, and all immune cells (lymphocytes macrophages monocytes, and lymphocytes) express P2X7. FutureWise Market Research has instantiated a report that provides an intricate analysis of P2X7 Receptor Antagonists Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the P2X7 Receptor Antagonists Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the P2X7 Receptor Antagonists Market: • GlaxoSmithKline Plc • Johnson and Johnson • AstraZeneca Plc • RaQualia Pharma • Evotec AG • Asahi Kasei Corporation • Pfizer (Note: The list of the major players will be updated with the latest market scenario and trends) P2X7 Receptor Antagonists Market Segmentation: By Drug Product • AKP-23494954/RQ-00466479 • EVT 401 • GSK1482160 • JNJ-55308942 • JNJ-54175446 • Others By Application • Central Nervous System Disorders • Immunological Disorders • Others By End-User • Hospital • Ambulatory Surgical Center • Pharmaceutical and Botechnology Companies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the P2X7 Receptor Antagonists Market By Drug Product, By Application, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
P2X7 receptor, an ATP-gated and non-selective cation channel that can regulate inflammatory disease has been implicated. The release of pro-inflammatory cytokines can be caused by the activation of the P2X7 channel by high levels of adenosine triphosphate (ATP). This has been linked to a wide range of diseases. There is currently no P2X7 antagonist on the market. Clinical trials have not yet begun to identify any P2X7 antagonists. P2X7R, a subtype of the seven purinergic P2X7 receptors that are ATP-gated, non-selective Cation Channels, is unique. There have been reports that P2X7R plays a pathological role in a variety of diseases, including arthritis, inflammatory bowel disease, neurodegenerative disorders, chronic pain, mood disorders, and cancers. Many pharmaceutical companies have attempted to develop a clinical candidate for P2X7R. P2X7 receptor, an ATP-gated and non-selective cation channel, is associated with a variety of inflammatory disorders. P2X7 receptor antagonists are therapeutic agents. Pain management is a common use of opioid medications. P2X7R, a subtype of the seven purinergic P2X receptors (ATP-gated nonselective Cation Channels), is unique. The pathological role of P2X7R in various diseases has been documented, including neurodegenerative diseases and chronic pain, mood disorders, cancers, and arthritis. A P2X7 Receptor Antagonist, or RA, is a pain medication that blocks the brain's activity of the ligand. The P2X7 Receptor is an important molecule that initiates inflammatory processes within the body. The approval and launch of an alternative pain management option are expected to be a breakthrough in this space. P2X7 has been linked to major depression. Animal studies have also shown that P2X7 antagonists can cause P2X7 to act in a way similar to antidepressants. Inflammation, mood disorders, and depression are all possible areas where P2X7 may be involved. Its antagonism could also help to modify treatment. Numerous research studies have shown that P2X7 channels are activated by the pro-inflammatory cytokines IL-1b, and IL-18. Extracellular ATP has a low affinity for P2X7, compared to other purinergic ion channel channels (P2X4, P2X3, etc.). The therapeutic benefits of P2X7 receptor antagonists are significant, since P2X7 receptors are associated with inflammation regulation, and all immune cells (lymphocytes macrophages monocytes, and lymphocytes) express P2X7. FutureWise Market Research has instantiated a report that provides an intricate analysis of P2X7 Receptor Antagonists Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the P2X7 Receptor Antagonists Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the P2X7 Receptor Antagonists Market: • GlaxoSmithKline Plc • Johnson and Johnson • AstraZeneca Plc • RaQualia Pharma • Evotec AG • Asahi Kasei Corporation • Pfizer (Note: The list of the major players will be updated with the latest market scenario and trends) P2X7 Receptor Antagonists Market Segmentation: By Drug Product • AKP-23494954/RQ-00466479 • EVT 401 • GSK1482160 • JNJ-55308942 • JNJ-54175446 • Others By Application • Central Nervous System Disorders • Immunological Disorders • Others By End-User • Hospital • Ambulatory Surgical Center • Pharmaceutical and Botechnology Companies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the P2X7 Receptor Antagonists Market By Drug Product, By Application, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. P2X7 Receptor Antagonists Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of P2X7 Receptor Antagonists Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. P2X7 Receptor Antagonists Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. P2X7 Receptor Antagonists Market, By Drug Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. AKP-23494954/RQ-00466479 7.2. EVT 401 7.3. GSK1482160 7.4. JNJ-55308942 7.5. JNJ-54175446 7.6. Others 8. P2X7 Receptor Antagonists Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Central Nervous System Disorders 8.2. Immunological Disorders 8.3. Others 9. P2X7 Receptor Antagonists Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital 9.2. Ambulatory Surgical Center 9.3. Pharmaceutical and Botechnology Companies 10. North America P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. GlaxoSmithKline Plc 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Johnson and Johnson 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. AstraZeneca Plc 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. RaQualia Pharma 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Evotec AG 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Asahi Kasei Corporation 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Pfizer 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics